Auni Juutilainen

List of Publications by Year
in descending order

35 papers	1,219 citations	706676 14 h-index	466096 32 g-index
35 all docs	35 docs citations	35 times ranked	2311 citing authors

#	Article	IF	Citations
1	Impact of minimal invasive extracorporeal circulation on perioperative intravenous fluid management in coronary artery bypass surgery. Perfusion (United Kingdom), 2023, 38, 135-141.	0.5	3
2	Serum caspase-cleaved cytokeratin-18 fragment as a prognostic biomarker in hematological patients with febrile neutropenia. Clinical and Experimental Medicine, 2022, 22, 83-93.	1.9	1
3	Preoperative atrial fibrillation in association with reduced haemoglobin predicts increased 30-d mortality after cardiac surgery. Scandinavian Cardiovascular Journal, 2021, 55, 109-115.	0.4	0
4	Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. Diabetes Care, 2021, 44, 1062-1069.	4.3	25
5	Febrile neutropenia in patients with acute myeloid leukemia: Outcome in relation to qSOFA score, Câ€�'reactive protein, and blood culture findings. European Journal of Haematology, 2020, 105, 731-740.	1.1	3
6	Plasma level of interleukin-18 and complicated course of febrile neutropenia in hematological patients after intensive chemotherapy. Cytokine, 2020, 129, 155021.	1.4	1
7	MMP-10 and TIMP-1 as indicators of severe sepsis in adult hematological patients with febrile neutropenia. Leukemia and Lymphoma, 2019, 60, 3036-3043.	0.6	4
8	Secular Trends in Infection-Related Mortality after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 755-762.	2.2	74
9	Changes in the microbiological epidemiology of febrile neutropenia in autologous stem cell transplant recipients. Infectious Diseases, 2018, 50, 436-442.	1.4	7
10	Novel Biomarker Candidates for Febrile Neutropenia in Hematological Patients Using Nontargeted Metabolomics. Disease Markers, 2018, 2018, 1-16.	0.6	5
11	Effector T Cell Resistance to Suppression and STAT3 Signaling during the Development of Human Type 1 Diabetes. Journal of Immunology, 2018, 201, 1144-1153.	0.4	21
12	Interleukinâ€'1 receptor antagonist as a biomarker of sepsis in neutropenic haematological patients. European Journal of Haematology, 2018, 101, 691-698.	1.1	4
13	Asymmetric dimethylarginine in the assessment of febrile neutropenia in hematological patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 130-134.	0.6	0
14	Old enemies in new disguises: emergence ofEnterococcus faeciumas a significant clinical problem at an adult haematology ward. Infectious Diseases, 2017, 49, 628-631.	1.4	3
15	Circulating CXCR5+PD-1+ICOS+ Follicular T Helper Cells Are Increased Close to the Diagnosis of Type 1 Diabetes in Children With Multiple Autoantibodies. Diabetes, 2017, 66, 437-447.	0.3	94
16	Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia. Disease Markers, 2017, 2017, 1-8.	0.6	20
17	Human plasma cell-free DNA as a predictor of infectious complications of neutropenic fever in hematological patients. Infectious Diseases, 2015, 47, 255-259.	1.4	13
18	Soluble form of urokinase-type plasminogen activator receptor as a diagnostic and prognostic marker in hematological patients with neutropenic fever. Leukemia and Lymphoma, 2014, 55, 718-721.	0.6	4

#	Article	IF	Citations
19	Combination of LCâ€"MS/MS aldosterone and automated direct renin in screening for primary aldosteronism. Clinica Chimica Acta, 2014, 433, 209-215.	0.5	29
20	Comparison of the MDRD Study and the CKD-EPI Study equations in evaluating trends of estimated kidney function at population level: findings from the National FINRISK Study. Nephrology Dialysis Transplantation, 2012, 27, 3210-3217.	0.4	14
21	Plasma copeptin in the assessment of febrile neutropenia. Peptides, 2012, 36, 129-132.	1.2	9
22	IL-10 combined with procalcitonin improves early prediction of complications of febrile neutropenia in hematological patients. Cytokine, 2012, 60, 787-792.	1.4	19
23	Trends in estimated kidney function: the FINRISK surveys. European Journal of Epidemiology, 2012, 27, 305-313.	2.5	23
24	Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. Scandinavian Journal of Infectious Diseases, 2011, 43, 471-478.	1.5	48
25	High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients. Haematologica, 2011, 96, 1385-1389.	1.7	42
26	Pentraxin 3 predicts complicated course of febrile neutropenia in haematological patients, but the decision level depends on the underlying malignancy. European Journal of Haematology, 2011, 87, 441-447.	1.1	8
27	Serum cortisol and inflammatory response in neutropenic fever. Annals of Hematology, 2011, 90, 1467-1475.	0.8	5
28	Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis. Leukemia and Lymphoma, 2011, 52, 2349-2355.	0.6	23
29	Thoracoabdominal Calcifications Predict Cardiovascular Disease Mortality in Type 2 Diabetic and Nondiabetic Subjects. Diabetes Care, 2010, 33, 583-585.	4.3	12
30	Serial plasma lactate measurements in haematological patients with neutropenic fever. Scandinavian Journal of Infectious Diseases, 2010, 42, 102-108.	1.5	5
31	Serum amino-terminal pro-brain natriuretic peptide in hematological patients with neutropenic fever: a prospective comparison with C-reactive protein. Leukemia and Lymphoma, 2010, 51, 1040-1046.	0.6	8
32	Serum vascular endothelial growth factor in adult haematological patients with neutropenic fever: a comparison with Câ€reactive protein. European Journal of Haematology, 2009, 83, 251-257.	1.1	12
33	Similarity of the Impact of Type 1 and Type 2 Diabetes on Cardiovascular Mortality in Middle-Aged Subjects. Diabetes Care, 2008, 31, 714-719.	4.3	168
34	Retinopathy Predicts Cardiovascular Mortality in Type 2 Diabetic Men and Women. Diabetes Care, 2007, 30, 292-299.	4.3	184
35	Gender Difference in the Impact of Type 2 Diabetes on Coronary Heart Disease Risk. Diabetes Care, 2004, 27, 2898-2904.	4.3	328